UCB to avoid capacity crunch for Cimzia with in-house manufacturing plant
This article was originally published in Scrip
Executive Summary
UCB of Belgium has decided to supplement its external production capacity for biologicals, in particular the rheumatoid arthritis and Crohn's disease treatment Cimzia (certoluzimab pegol), by building an in-house biotech microbial manufacturing plant in Bulle, Switzerland.